Yazar "Lugaresi, A." için listeleme
-
Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.
Spelman, T.; Harvrdova, E. K.; Horakova, D.; Izquierdo, G.; Kalincik, T.; Lugaresi, A.; McCombe, P. (Sage Publications Ltd, 2018)… -
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS
Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)… -
Contribution of inflammation to disability accrual in primary progressive multiple sclerosis
Hughes, J.; Jokubaitis, V.; Spelman, T.; Lugaresi, A.; Hupperts, R.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2017)… -
Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis
Lizak, N.; Lugaresi, A.; Alroughani, R.; Lechner-Scott, J.; Slee, M.; Havrdova, E.; Rio, M. E. (Sage Publications Ltd, 2015)… -
Independent predictors of time to relapse after CIS in high-risk patients
Spelman, T.; Meyniel, C.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Grand'Maison, F.; Butzkueven, H. (Sage Publications Ltd, 2014)…
